07X Stock Overview A clinical stage drug platform company, develops drugs to treat neurodegeneration. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Annovis Bio, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Annovis Bio Historical stock prices Current Share Price US$4.83 52 Week High US$16.20 52 Week Low US$4.16 Beta 1.64 1 Month Change -13.38% 3 Month Change -33.45% 1 Year Change -58.83% 3 Year Change -68.87% 5 Year Change n/a Change since IPO 1.92%
Recent News & Updates
Annovis Bio, Inc. Announces FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway Jan 07 Annovis Bio, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Dec 11
New major risk - Revenue and earnings growth Oct 25
FDA Clears Annovis Bio Inc. to Launch Pivotal Phase 3 Alzheimer’s Studies Oct 15
New minor risk - Market cap size Oct 15
Annovis Bio, Inc. Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra Oct 01 See more updates
Annovis Bio, Inc. Announces FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway Jan 07 Annovis Bio, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Dec 11
New major risk - Revenue and earnings growth Oct 25
FDA Clears Annovis Bio Inc. to Launch Pivotal Phase 3 Alzheimer’s Studies Oct 15
New minor risk - Market cap size Oct 15
Annovis Bio, Inc. Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra Oct 01
New major risk - Revenue and earnings growth Aug 18
Annovis Bio Inc. Lead Compound Enhances Cognition Synergistically with Glp-1 Agonist Aug 07
Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap Jul 16
Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team Jul 09
Annovis Bio Inc. Announces New Data from Phase III Parkinson's Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition After Treatment with Buntanetap Jul 03
Annovis Bio, Inc. Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap Jun 28
Annovis Bio Files Patent for New Composition of Matter for Buntanetap Jun 27
New major risk - Revenue and earnings growth Jun 10
New major risk - Financial position May 13
Annovis Bio, Inc. Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease May 10
New major risk - Revenue and earnings growth May 01
Insufficient new directors May 01
Annovis Bio, Inc., Annual General Meeting, Jun 12, 2024 May 01
Annovis Bio, Inc. Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease Apr 30
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans Apr 03
New major risk - Negative shareholders equity Mar 31 Annovis Bio, Inc. has completed a Follow-on Equity Offering in the amount of $2.999993 million. Mar 23
Annovis Bio, Inc. has filed a Follow-on Equity Offering in the amount of $2.999993 million. Mar 22
Annovis Bio, Inc. Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease
Annovis Bio, Inc. Announces Last Patient Last Visit in Phase II/III Study of Buntanetap in Alzheimer's Disease Feb 15
Annovis Bio, Inc. Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio Jan 31
Annovis Bio, Inc. Refines Timeline for Parkinson's Phase III Study Data Announcement Jan 24
New major risk - Revenue and earnings growth Dec 06
Annovis Bio, Inc. Announces Last Patient Last Visit in Phase III Study of Buntanetap in Parkinson’s Disease Dec 05
Annovis Bio, Inc. Announces Full Enrollment of Its Phase II/III Alzheimer's Disease Trial, Exceeding Original Projects Nov 29
Annovis Bio, Inc. Announces Full Enrollment of Its Phase II/III Alzheimer's Disease Trial, Exceeding Original Projects Nov 28 Annovis Bio, Inc. has completed a Follow-on Equity Offering. Nov 02
Annovis Bio, Inc. Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board Oct 31
Annovis Bio, Inc. Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference Oct 25
Annovis Bio, Inc. Announces Positive Interim Analysis for Clinical Power in its Alzheimer's Study Oct 14
New minor risk - Share price stability Oct 13
Annovis Bio, Inc. Presents Three Posters At Alzheimer's Association International Conference Jul 21
Annovis Bio, Inc. Announces Creation of A Novel Crystalline Form of Buntanetap (Anvs402), and the Filing of A New Composition of Matter Provisional Patent with the U.S. Patent and Trademark Office Jun 28
Annovis Bio, Inc. Receives Positive Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB) Jun 21
Annovis Bio, Inc. Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease Feb 09
Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses Feb 02
Annovis Bio, Inc. Announces Patient Enrollment Update for Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease Jan 26
Annovis Bio Announces Publication of Phase 2a Clinical Data in the Journal of Prevention of Alzheimer's Disease Oct 12
Annovis Bio, Inc. Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease Oct 07
Annovis Bio, Inc. Announces Executive Changes Aug 31
Annovis Bio, Inc. Appoints Henry Hagopian III as Chief Financial Officer Aug 30
Annovis Bio, Inc. Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease Aug 25
Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease Jul 09 Annovis Bio Announces That the Company Submitted an International Patent Application Under the Patent Cooperation Treaty for Its Drug Platform Buntanetap
Annovis Bio, Inc., Annual General Meeting, Jun 02, 2022 Apr 19
Independent Director recently bought €119k worth of stock Oct 14
Pomerantz LLP Reminds Shareholders with Losses on Their Investment in Annovis Bio, Inc. of Class Action Lawsuit Oct 02
Bernstein Liebhard LLP Files Securities Class Action Lawsuit Against Annovis Bio, Inc Aug 19
Independent Director has left the company Mar 17
Annovis Bio, Inc. Announces Board Changes Mar 17
Annovis Bio, Inc. Enters into Agreement with Wilmington PharmaTech Company, LLC Mar 16
New 90-day high: €23.80 Feb 20
New 90-day high: €8.50 Jan 20
New 90-day high: €6.25 Jan 05
New 90-day high: €5.00 Dec 18
New 90-day high: €4.76 Nov 27
Annovis Bio, Inc. Reports Positive Results from Final Phase of NIH Funded Chronic Toxicology Study for Its Lead Compound for the Treatment of Alzheimer’S and Parkinson’S Diseases Nov 13
Annovis Bio Resumes Treatment of Patients in Ongoing Phase 2a Study in Alzheimer’s Disease After COVID-Related Delay Oct 30
Annovis Bio, Inc. Demonstrates Improved Axonal Transport in Nerve Cells and Brain of Down Syndrome Mice, an Animal Model of Alzheimer’s Disease Sep 30 Shareholder Returns 07X DE Biotechs DE Market 7D -2.8% 6.0% 1.7% 1Y -58.8% -5.6% 9.4%
See full shareholder returns
Return vs Market: 07X underperformed the German Market which returned 9.6% over the past year.
Price Volatility Is 07X's price volatile compared to industry and market? 07X volatility 07X Average Weekly Movement 11.4% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 07X's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 07X's weekly volatility has decreased from 21% to 11% over the past year, but is still higher than 75% of German stocks.
About the Company Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company’s lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer’s disease (AD), Parkinson’s disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia.
Show more Annovis Bio, Inc. Fundamentals Summary How do Annovis Bio's earnings and revenue compare to its market cap? 07X fundamental statistics Market cap €67.56m Earnings (TTM ) -€39.69m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 07X income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$40.94m Earnings -US$40.94m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/08 02:57 End of Day Share Price 2025/01/08 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Annovis Bio, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Tyler Bussian Brookline Capital Markets Sumant Satchidanand Kulkarni Canaccord Genuity Jason Kolbert D. Boral Capital LLC.
Show 3 more analysts 
